Biopharmaceutical companies Protagonist Therapeutics (NASDAQ: PTGX) and Takeda (TSE: 4502) (NYSE: TAK) on Monday announced positive topline results from the Phase 3 VERIFY study evaluating rusfertide in phlebotomy-dependent patients with polycythemia vera (PV). The study met its primary endpoint, with 77% of rusfertide-treated patients achieving clinical response compared to 33% in the placebo group (p
Akeso completes patient enrolment for cadonilimab Phase III registrational clinical trial
Jazz Pharmaceuticals to acquire Chimerix in USD935m deal to expand oncology portfolio
Dermata Therapeutics completes treatment in XYNGARI Phase 3 acne trial
Bloom Science's BL-001 shows positive results in Phase 1 trial
Heyou Hospital, China orders treatment planning system from RaySearch
ONWARD Medical secures funding to advance Parkinson's disease research
Latigo Biotherapeutics' LTG-001 receives US FDA Fast Track designation
Raziel and Fosun Pharma commence phase 3 RZL-012 study in China
CStone Pharmaceuticals reports first patient dosed in CS2009 Phase I trial
Celltrion's STOBOCLO and OSENVELT biosimilars receive US FDA approval
Faron Pharmaceuticals' bexmarilimab receives FDA Orphan Drug Designation for MDS
Protagonist and Takeda report positive Phase 3 results for rusfertide in polycythemia vera
GSK demonstrates significant improvement in CRSwNP treatment with depemokimab at 2025 AAAAI
Australia declines approval for BioArctic and Eisai's Alzheimer's drug lecanemab